KEYMED BIO-B (02162.HK): Exclusive License Agreement for Stapokibart Covering 18 Countries and Regions Including Southeast Asia and Central Asia

NewTimeSpace News: On 2 September 2026, Keymed Biosciences Inc. (stock code: 02162.HK) announced, on a voluntary basis, that the Company had signed an exclusive license agreement with multinational pharmaceutical company Aeira Pte. Ltd. (Aeira) to collaborate on the registration and commercialization of Stapokibart injection (trade name: Kangyueda), an IL-4Rα-targeting monoclonal antibody developed in-house by the Company, in Southeast Asia and Central Asia.
Under the agreement, Keymed will receive an upfront payment, milestone payments upon approval of marketing applications in different countries and commercialization milestone payments, and is entitled to royalties of up to high-double-digit rates calculated on the net sales of the product in the licensed territories.
Aeira will be responsible for the regulatory filings and commercialization of Stapokibart in 11 countries in Southeast Asia (Brunei Darussalam, Cambodia, Indonesia, the Lao People's Democratic Republic, Malaysia, Myanmar, the Philippines, Singapore, Thailand, Timor-Leste and Vietnam), 5 countries in Central Asia (Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan and Uzbekistan), and the Hong Kong Special Administrative Region and the Macao Special Administrative Region — 18 countries and regions in total. Keymed will continue to be responsible for the manufacture and supply of Stapokibart for Aeira.
Stapokibart (trade name: Kangyueda, R&D codename: CM310) is the first domestically developed IL-4Rα antibody drug granted marketing approval by the NMPA, with its indications for moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyposis and seasonal allergic rhinitis approved for marketing in September 2024, December 2024 and February 2025, respectively. The collaboration marks an important milestone in Keymed's internationalization strategy for innovative biologics, leveraging the partner's unique commercial networks and registration experience in Southeast Asia and Central Asia to accelerate the launch and commercialization of Stapokibart in these regions.

View announcement.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.